Advertisement

European Society for Vascular Surgery (ESVS) AAA Guidelines Focused Update on patients treated with the Nellix EndoVascular Aneurysm Sealing (EVAS) system

Open AccessPublished:January 06, 2023DOI:https://doi.org/10.1016/j.ejvs.2022.12.031
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Objective

      To provide guidance on the surveillance and management of patients treated with Endovascular Aneurysm Seal (EVAS).

      Method

      Based on a scoping review of risk for late serious aortic-related adverse events in patients treated with EVAS for AAA, the European Society for Vascular Surgery (ESVS) AAA Clinical Practice Guidelines Writing Committee agreed on recommendations graded according to the European Society of Cardiology (ESC) grading system.

      Results

      EVAS has a very high incidence of late endograft migration resulting in proximal type 1 endoleak with risk of rupture, requiring open conversion with device explant. The reported mortality for elective explantation varies between 0% and 14%, while acute conversion for rupture has a very dismal prognosis with 67-75% mortality.

      Conclusion

      It is recommended that all patients in whom a Nellix device has been implanted should be identified, properly informed and enrolled in enhanced surveillance. If device failure is detected, early elective device explant should be considered in surgically fit patients.

      Keywords

      Comments

      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.